The House Committee on Appropriations May 8 approved a spending bill that gives NIH $41.1 billion, a $2 billion increase over the current level. The bill passed on a vote of 30 to 23.
Early endpoints have the potential to get effective drugs to patients faster, but granting approval to drugs—even accelerated approval—comes with the risk that ineffective or even harmful drugs will be given to patients.
